Benefits seemed very situational, especially for EGFR expression, but the future does seem to be personalized medicine, and this could be another piece to that puzzle.
>> Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline.
